|
KMID : 1143420220150020082
|
|
Public Health Weekly Report
2022 Volume.15 No. 2 p.82 ~ p.90
|
|
|
Monitoring status of adverse events following immunization on the third dose of
|
|
Ko Mi-Jeong
Lee Yeon-Kyeng
Kwon Yun-Hyung
Hwang In-Sob
Kim Seon-Tae
Kim Hyung-Jun
|
|
|
Abstract
|
|
|
The incidence of coronavirus disease 2019 (COVID-19) remains prevalent despite vaccine administration because of the
worldwide spread of the Delta variant. The requirement for a third dose of the COVID-19 vaccine has emerged due to a
reduction in the effectiveness of the vaccines over time. Thus, in the Republic of Korea (ROK), the third dose of the COVID-19 vaccine has been administered sequentially since October 12, 2021, starting from persons at high-risk for severe COVID-19, to better protect the population from the infection, the severity of the disease, and death from COVID-19. In order to identify and respond to the incidence of adverse events (AEs) following COVID-19 vaccinations, a monitoring survey was conducted via mobile texts. This report analyzed the suspected AEs reported in the Korea Immunization Management System (KIMS) for COVID-19 from February 26, 2021, to November 20, 2021, and the responses of a survey on the AEs and health status of individuals who received the third dose of the vaccine between November 1, 2021, and November 8, 2021, from days 0 to 7 of receiving the third dose. In the case of the Janssen vaccine, as the primary vaccination series (first and second dose) is considered complete after the first dose, a second dose of the Janssen vaccine was classified as the third dose. According to an analysis of the suspected AEs reported in the KIMS during the observation period, 96.4% of the reported cases showed non-serious AEs and 3.6% were serious AEs. Moreover, as the number of doses increased, the number of reports of suspected AEs decreased. According to the results of the mobile text monitoring survey, the incidence of AEs was the lowest among those who received the Pfizer vaccine for all three doses (30.4%) and the highest among those who received one dose of the Janssen vaccine followed by a second dose of the Moderna vaccine (45.7%). Among the local AEs the most common response was pain at the injection site, while the most common systemic AEs were myalgia, fatigue/ tiredness, and headache. This report presents a preliminary analysis of the AEs of the third dose of the COVID-19 vaccine in the ROK to identify safety information on the third dose. In the future, AEs will continue to be monitored and relevant information will be shared and reviewed with experts to promote a safe COVID-19 vaccination program
|
|
|
KEYWORD
|
|
|
COVID-19 vaccination, Third dose, Adverse events
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|